Erdafitinib news

All news on Erdafitinib (also known as Balversa): plants, production capacities, investments and involved companies.

13 March 2026

Johnson & Johnson Reports Positive Phase 1 Results for Erda-iDRS in Bladder Cancer

Erda-iDRS shows safety and efficacy in Phase 1 for intermediate-risk bladder cancer, with high complete response rates and ongoing Phase 2 and 3 studies.

Who will be producing Erdafitinib in the future?

Find out with chemXplore Alpha

Learn more